Trademarks / Patents / IP Patents for Phillippe Wolgen (with Roland Callens as co-inventor in some of them)

macgyver

Well-known member
  • PHARMACEUTICAL COMPOUND
    Publication number: 20200095303
    Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 26, 2020
    Inventors: Philippe WOLGEN, Roland CALLENS
  • Pharmaceutical compound
    Patent number: 10508142
    Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 17, 2019
    Assignee: VALLAURIX PTE. LTD.
    Inventors: Philippe Wolgen, Roland Callens
  • PHARMACEUTICAL COMPOUND
    Publication number: 20180094039
    Abstract: The present invention relates to compounds comprising a quaternary ammonium group, their use in skin diseases, and their preparation.
    Type: Application
    Filed: April 28, 2016
    Publication date: April 5, 2018
    Inventors: Philippe WOLGEN, Roland CALLENS
  • PHARMACEUTICAL COMPOUND
    Publication number: 20180086789
    Abstract: The present invention relates to an alpha-MSH analogue compound, the use in skin diseases, and the preparation.
    Type: Application
    Filed: April 28, 2016
    Publication date: March 29, 2018
    Inventors: Philippe WOLGEN, Roland CALLENS
  • THERAPY FOR VITILIGO
    Publication number: 20180008676
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 11, 2018
    Inventor: Philippe Wolgen
  • INFLAMMATORY DISEASE
    Publication number: 20170360896
    Abstract: The present invention is directed to alpha-MSH analogues for treatment of inflammatory disease.
    Type: Application
    Filed: October 28, 2015
    Publication date: December 21, 2017
    Inventor: Philippe WOLGEN
  • Therapy for vitiligo
    Patent number: 9801924
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analog either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 31, 2017
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • NEW INDICATION FOR ALPHA-MSH ANALOGUES
    Publication number: 20170304406
    Abstract: The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders.
    Type: Application
    Filed: October 28, 2015
    Publication date: October 26, 2017
    Inventor: Philippe WOLGEN
  • METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS
    Publication number: 20130344153
    Abstract: A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage.
    Type: Application
    Filed: September 3, 2013
    Publication date: December 26, 2013
    Inventor: Philippe Wolgen
  • HEXAPEPTIDE WITH IMPROVED ACTIVITY IN THE REPAIR OF CELLULAR DNA OF DERMAL CELLS
    Publication number: 20130331331
    Abstract: The present invention relates to a compound having a structure selected from: Ac-Nle-Glu-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 1); or Ac-Nle-Gln-His-D-Phe-Arg-Trp-NH2 (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof. The compound of the salt thereof are particularly useful for the repair or prevention of damage of cellular DNA of dermal (skin) cells following UV irradiation in a mammal.
    Type: Application
    Filed: February 13, 2012
    Publication date: December 12, 2013
    Inventor: Philippe Wolgen
  • Method of treatment of photodermatoses
    Patent number: 8334265
    Abstract: This invention relates to a method for prophylactic or therapeutic treatment of photodermatoses that are caused or exacerbated by or associated with UVR exposure in a subject, particularly a human subject, which comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to reduce the photosensitivity of the skin of the subject.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: December 18, 2012
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • THERAPY FOR VITILIGO
    Publication number: 20110130705
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Application
    Filed: March 27, 2009
    Publication date: June 2, 2011
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS
    Publication number: 20100113337
    Abstract: A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage.
    Type: Application
    Filed: August 28, 2007
    Publication date: May 6, 2010
    Applicant: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
 

CUV Quote (Yesterday's close)

Time: 2:49PM AEST
Price: 29.03
Volume: 33312
Top